Abstract
Angiogenesis inhibition is now a proven therapeutic strategy in treatment of several solid tumors. Vatalanib is a potent inhibitor of all known vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. In view of the effectiveness of angiogenesis inhibitor therapy when combined with chemotherapy and the established role of capecitabine in treatment of colorectal and breast cancer, we undertook a phase I clinical trial of the combination of capecitabine and vatalanib with the goal of developing a combination oral regimen. The study objectives were to determine the maximally tolerated dose of vatalanib that could be safely administered daily with capecitabine given orally for 14 out of 21 days to patients with advanced cancer; to characterize the safety, tolerability, and pharmacokinetic profile of vatalanib given in combination with capecitabine; and to describe any pharmacokinetic interactions between the drugs. The study had an initial dose escalation phase followed by a dose expansion phase. During the dose escalation phase, cohorts of at least three patients each were treated with capecitabine and escalating doses of vatalanib until the maximally tolerated dose of vatalanib was determined. Vatalanib given continuously at a dose of 1,250 mg/day could be safely combined with capecitabine at a dose of 2,000 mg/m2/day given for 14 of 21 days. Dose-limiting toxicities of the combination included fatigue, hypertension, dizziness, and proteinuria. Vatalanib did not alter the pharmacokinetics of 5-FU, the active metabolite of capecitabine. Vatalanib and capecitabine can be safely combined without unexpected toxicities or significant pharmacokinetic interactions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
Sandler A, Gray R, Perry M et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355(24):2542–2550
Miller KD, Wang M, Gralow J et al (2005) E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer. Proc Am Soc Clin Oncol 2005 Annual Meeting (abstract)
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134
Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434
Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027
Wood JM, Bold G, Buchdunger E et al (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189
Drevs J, Hofmann I, Hugenschmidt H et al (2000) Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819–4824
Solorzano CC, Baker CH, Bruns CJ et al (2001) Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16(5):359–370
Kim S, Yazici YD, Barber SE et al (2006) Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK 7787/ZK 222584 and CPT-11. Head Neck 28(5):389–399
Thomas AL, Morgan B, Horsfield MA et al (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23(18):4162–4171
Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21(21):3955–3964
Roboz GJ, Giles FJ, List AF et al (2006) Phase I study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20:952–957
Scott EN, Meinhardt G, Jacques C et al (2007) Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs 16:367–379
PTK787/ZK222584 Investigator Brochure
Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097–4106
Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19(8):2282–2292
O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20(12):2812–2823
Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40(2):85–104
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Instit 92:205–216
Hecht JR, Trarbach T, Jaeger E et al (2005) A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 2005 ASCO Annual Meeting Proceedings 23(16S, I):3
Koehne C, Bajetta E, Lin E et al (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients) with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 (Vatalanib) or placebo (CONFIRM-2). J Clin Oncol 2006 ASCO Annual Meeting Proceedings 24(18S):3508
Jost LM, Gschwind H-P, Jalava T et al (2006) Metabolism and disposition of vatalanib (PTK787/ZK 222584) in cancer patients. Drug Metab Dispos 34(11):1817–1828
Acknowledgements
Supported in part by a grant from Novartis Oncology, Inc. Acknowledgements to Dr. Lily Zhao from Novartis for conducting the statistical analysis of PK parameters.
Conflict of interest statement
Although the authors have not received and will not receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article, benefits have been received but are directed solely to an educational institution with which one or more of the authors are associated. Four authors are employees of Novartis Oncology and one is an employee of Bayer Schering Pharma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schilsky, R.L., Geary, D., Skoog, L. et al. Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer. Targ Oncol 3, 3–11 (2008). https://doi.org/10.1007/s11523-007-0070-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-007-0070-5